These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11781637)

  • 21. Immunosuppressive treatment of severe acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Zupan IP; Zver S; Pretnar J
    Transplant Proc; 2002 Nov; 34(7):2931-3. PubMed ID: 12431662
    [No Abstract]   [Full Text] [Related]  

  • 22. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease.
    Fricain JC; Sibaud V; Swetyenga N; Tabrizi R; Campana F; Taïeb A
    Br J Dermatol; 2007 Mar; 156(3):588-90. PubMed ID: 17300261
    [No Abstract]   [Full Text] [Related]  

  • 24. Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia.
    Dilek I; Demirer T; Ustün C; Arat M; Koç H; Beksaç M; Erdi H; Anadolu R; Ozcan M; Ilhan O; Akan H
    Bone Marrow Transplant; 1998 Jun; 21(11):1159-61. PubMed ID: 9645582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy.
    Hoffner MV; Carrizosa Esquivel A; Pulpillo Ruiz A; Herrera Saval A; Conejo-Mir J; Camacho FM
    J Drugs Dermatol; 2009 Nov; 8(11):1027-9. PubMed ID: 19894371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
    Mori M; Muroi K; Matsuyama T; Oka S; Ono Y; Yamamoto C; Uesawa M; Okabe H; Matsu H; Tatara R; Kikuchi Y; Fujiwara S; Kikuchi S; Sato K; Ueda M; Toshima M; Ozaki K; Takatoku M; Nagai T; Ozawa K
    Rinsho Ketsueki; 2007 Aug; 48(8):624-31. PubMed ID: 17867298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel approaches in GVHD therapy.
    Svennilson J
    Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S65-7. PubMed ID: 15812534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sclerodermiform chronic graft-versus-host disease after allogenic peripheral blood stem-cell transplantation].
    Neid T; Danz B; Eismann R; Bramsiepe I; Wohlrab J; Marsch WC; Fiedler E
    Dtsch Med Wochenschr; 2009 May; 134(21):1106-9. PubMed ID: 19437374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
    Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
    Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Li JP; Zhang T; Zhong J; Chen J
    Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic stem cell transplantation for Evans syndrome.
    Oyama Y; Papadopoulos EB; Miranda M; Traynor AE; Burt RK
    Bone Marrow Transplant; 2001 Nov; 28(9):903-5. PubMed ID: 11781654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
    Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment.
    Holler E
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):281-94. PubMed ID: 17448962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?
    Levine JE
    Pediatr Transplant; 2015 Sep; 19(6):582-3. PubMed ID: 26215797
    [No Abstract]   [Full Text] [Related]  

  • 36. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular graft-versus-host disease: a review.
    Shikari H; Antin JH; Dana R
    Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
    Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
    Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chronic graft-versus-host disease presenting as bullous lesions].
    del Pozo J; García-Silva J; Yebra-Pimentel MT
    Actas Dermosifiliogr; 2008 Dec; 99(10):803-7. PubMed ID: 19091220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.